Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,158.73 +30.94 (+0.60%) Dow
38,818.92 +143.24 (+0.37%) Nasdaq
16,255.81 +99.48 (+0.62%) Bitcoin USD
64,165.10 +295.59 (+0.46%) CMC Crypto 200
1,379.18 +66.55 (+5.07%)
Humacyte, Inc. (HUMA)
| Previous close | 4.4100 |
| Open | 4.4900 |
| Bid | 4.3900 x 800 |
| Ask | 4.4600 x 400 |
| Day's range | 4.3200 - 4.5400 |
| 52-week range | 1.9600 - 5.6000 |
| Volume | |
| Avg. volume | 1,429,890 |
| Market cap | 526.351M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0700 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
GlobeNewswireHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Friday, May 10, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2024 Financial Results and Corporate UpdateDa
- GlobeNewswire
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Thursday, March 28, 2024 at 8:00 AM ET, featuring Timmy Lee, MD, MSPH (University of Alabama at Birmingham) and Prabir Roy-Chaudhury MD, PhD, FRCP (University of North Carolina School of Medicine) who will discuss the profiles of patien
Insider MonkeyHumacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript March 22, 2024 Humacyte, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte 2023 Fourth Quarter Year-End Results Conference Call. Currently, all […]
